Concordant with previous reports that CITED2 promotes prostate cancer metastasis45, Boyden chamber Matrigel invasion assays showed that degradation of p300/CBP markedly reduced the invasion ability of LNCaP and 22Rv1 cells, whereas significant changes were not observed with p300/CBP bromodomain inhibitors (Extended Data Fig. 7k). The gene discussed is EP300; the disease is prostate carcinoma.